(Reuters) -Telehealth firm LifeMD said on Tuesday it would offer Danish drugmaker Novo Nordisk's diabetes drug Ozempic at $499 per month to eligible U.S. patients. Eligible self-pay and uninsured ...

Danish drugmaker Novo Nordisk's India Head, Vikrant Shrotiya, shares that the pharmaceutical giant is ready to launch Ozempic ...

LifeMD (LFMD) stock is in focus as the firm expands its telehealth collaboration with Novo Nordisk to offer the pharma ...

Ozempic® is now available at this reduced price to eligible self-pay LifeMD patientsNEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care ...

Morgan Stanley analyst Thibault Boutherin pointed to slowing momentum in U.S. prescriptions for Novo's flagship GLP-1 drugs, ...

Novo Nordisk has received CDSCO approval for its blockbuster drug Ozempic, completing its semaglutide portfolio in India as ...

Eligible self-pay and uninsured patients, as well as insured patients whose plans do not cover GLP-1 therapies, will have ...

Drugmaker Novo Nordisk is set to cut jobs at its Irish unit. The Danish firm notified the Department of Enterprise of ...

Danish pharmaceutical company Novo Nordisk, the maker of blockbuster drugs Ozempic and Wegovy, is planning job cuts at its Irish operation.

Department of Enterprise, Tourism and Employment received a collective redundancy notification from Novo Nordisk earlier this month.

Novo Nordisk stock fell after Morgan Stanley said Ozempic and Wegovy prescription growth is stagnating, and recommended ...

Telehealth firm LifeMD said on Tuesday it would partner with Novo Nordisk to offer its diabetes drug Ozempic at $499 per ...